RCS - Cydar Ltd - First patient treated in Medtronic collaboration

ReachAnnouncement

23/08/2023 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230823:nRSW1301Ka&default-theme=true

RNS Number : 1301K  Cydar Ltd  23 August 2023

RNS REACH - PRESS RELEASE

 

 

CYDAR MEDICAL ANNOUNCES FIRST PATIENT TREATED IN GLOBAL STRATEGIC
COLLABORATION WITH MEDTRONIC

 

40-site pilot program across US, UK and Europe aims to introduce cutting edge
AI solutions into the clinical environment to improve patient care and
efficiency

 

Cydar Maps used to successfully treat first patient at Edward Hospital, IL, US

 

 

CAMBRIDGE, UNITED KINGDOM, 23 AUGUST 2023 - Cydar Medical ("Cydar" or "the
Company") a global, cloud-based surgical software company, announces the
successful treatment of the first patient in a strategic collaboration with
Medtronic, a global leader in medical technology, services and solutions. The
collaboration, which spans 40 sites across the United States, UK and Europe,
involves the integration of the Company's Cydar Maps software with Medtronic's
services and case support, with the aim of improving patient care and the
efficiency of medical professionals by introducing unique artificial
intelligence ("AI") solutions into the clinical environment.

 

The first patient in the pilot program was treated using Cydar Maps at Edward
Hospital, in Illinois by vascular and endovascular surgeon, Dr George
Pontikis, MD.

 

Cydar Maps is the first product from Cydar's cutting-edge AI technology
platform and transforms the way information is provided to clinicians
undertaking image-guided minimally invasive surgery ("MIS") simplifying
complexities within operating theatres at leading hospitals across the globe.
Cydar Maps generates a 3D map of patient soft tissue to support and integrate
pre-operative planning, intra-operative guidance and post-operative review of
endovascular MIS, using AI to update the map throughout the patient journey.
Cydar Maps has been shown to offer a number of benefits, including halving the
radiation exposure for patients and the clinical team, simplifying the
clinical workflow and increasing clinician confidence, which in turn can
significantly reduce procedure times(1-3). The pilot program is also expected
to inform the on-going development of Cydar Maps which will include predictive
analytics to support optimised procedure planning based on the use of AI to
compare patient anatomy and procedure outcomes from a global data set.

 

George Pontikis, MD Vascular surgeon at Edward Hospital, said:

"This cutting-edge technology empowers us with the ability to navigate complex
vascular procedures with greater precision- ensuring optimal outcomes for our
patients. We are honoured to be a part of this innovative program and are
eager to contribute to the advancement of endovascular aortic surgery."

 

Paul Mussenden, Chief Executive Officer of Cydar Medical commented:

"This is an important milestone for Cydar, to be working with Medtronic to
accelerate the adoption of our AI-solution by the global endovascular
community," said Paul Mussenden, CEO of Cydar. "The goal is to provide
clinicians with a more predictable and efficient way to perform minimally
invasive image-guided procedures. We look forward to supporting the treatment
of additional patients across the planned 40 sites and to continue the
introduction of the exciting product developments we have planned over the
course of the year ahead."

 

- ENDS -

 

 

For further information, please visit www.cydarmedical.com
(http://www.cydarmedical.com) or contact:

 

 Cydar Medical
 Paul Mussenden, Chief Executive Officer                       contact@cydar.co.uk (mailto:contact@cydar.co.uk)
 Cynthia Azucena, Global Marketing Director
 Emma Deanfield, Head of Investor Relations & Fundraising

 FTI Consulting                                                +44 (0)20 3727 1000
 Ben Atwell / Alex Davis                                       CydarMedical@fticonsulting.com (mailto:CydarMedical@fticonsulting.com)

 

 

About Cydar Medical

 

Cydar Medical is a global cloud-based software company that provides an
integrated solution for planning, navigation and review of surgical procedures
using the power of artificial intelligence ("AI") to augment a clinician's
decision making. Its Cydar Maps product harnesses the latest in cloud graphics
processing unit computing, computer vision and machine learning technology to
advance surgical visualisation and decision-making in theatre, and across the
surgical pathway. The Company's AI will continue to learn from procedures
conducted globally to provide predictive analytics to assist clinicians in the
operating room, enabling them to make faster, easier and safer decisions in
the future. The platform will deliver new products and capabilities to improve
the delivery of healthcare. Cydar Medical is headquartered in Cambridge,
United Kingdom, and is working towards its vision of advancing the quality of
care for patients in a world where all surgery conducted works exactly as
planned.

 

For further information, please visit www.cydarmedical.com
(http://www.cydarmedical.com)

 

References and Notes

 

(1) Shortell C, Veith Symposium New York, 2017

 

(2) Southerland et al. Image-Based Three-Dimensional Fusion Computed
Tomography Decreases Radiation Exposure, Fluoroscopy Time, and Procedure Time
During Endovascular Aortic Aneurysm Repair. Journal of Vascular Surgery
Abstracts e61. Volume 67, Number 6

 

(3) Blandine et al. A prospective observational trial of fusion imaging in
infrarenal aneurysms J Vasc Surg. 2018 Dec;68(6):1706-1713.e1. doi:
10.1016/j.jvs.2018.04.015. Epub 2018 May 24.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGZRVZDGFZM